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a b s t r a c t
Chronic exposure to inorganic arsenic (iAs) is carcinogenic to the human urinary bladder. It produces
urothelial cytotoxicity and proliferation in rats and mice. DMAV , a major methylated urinary metabolite
of iAs, is a rat bladder carcinogen, but without effects on the mouse urothelium. DMAIII was shown to
be the likely urinary metabolite of DMAV inducing urothelial changes and is also postulated to be one
of the active metabolites of iAs. To evaluate potential DMAIII -induced urothelial effects, it was administered to As3mt knockout mice which cannot methylate arsenicals. Female C57BL/6 wild type and As3mt
knockout mice (10/group) were administered DMAIII , 77.3 ppm in water for four weeks. Urothelial effects
were evaluated by light and scanning electron microscopy (EM) and immunohistochemical detection of
bromodeoxyuridine (BrdU) incorporation. EM ﬁndings were rated 1–5, with higher rating indicating
greater extent of cytotoxicity visualized. DMAIII signiﬁcantly increased the BrdU labeling index, a ratio
of BrdU labeled cells to non-labeled cells, in the treated knockout group compared to control and wild
type treated groups. DMAIII induced simple hyperplasia in more knockout mice (4/10) compared to wild
type mice (2/10). All treated knockout mice had more and larger intracytoplasmic granules compared
to the treated wild type mice. Changes in EM classiﬁcation were not signiﬁcant. In conclusion, DMAIII
induces urothelial toxicity and regenerative hyperplasia in mice and most likely plays a role in inorganic
arsenic-induced urothelial changes. However, DMAV does not induce hyperplasia in mice, suggesting
that urinary concentrations of DMAIII do not reach cytotoxic levels in DMAV -treated mice.
© 2013 Elsevier Ireland Ltd. All rights reserved.

1. Introduction
Inorganic arsenic (iAs) is a known human carcinogen producing tumors in urinary bladder, liver, lung, and skin (National
Research Council, 1999, 2001). This metalloid occurs mainly in
the +5 (arsenate) or +3 (arsenite) oxidation states, and is the
20th most abundant chemical in the earth’s crust (IARC, 2004).
Because it is present in soils, it can be leached into ground water.
As-contaminated ground water is used as drinking water by populations worldwide and constitutes an important source of exposure
to this toxicant that is associated with increased incidence of both
cancer and non-cancer health effects (Chiou et al., 1995). Although
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dose–response relations for these adverse health effects are not
fully understood (Lamm et al., 2006), it is clear that arsenic exposure contributes to tumor risk (National Research Council, 1999,
2001).
Elucidating the processes underlying the adverse health effects
of chronic arsenic exposure is complicated by the extensive
metabolism that follows ingestion or inhalation of iAs. Mono-, di-,
and trimethylated metabolites are found in tissues and excreta of
animals exposed to iAs. The formation of methylated arsenicals
is catalyzed in many mammalian species by arsenic (3+ oxidation
state) methyltransferase (As3mt) (Thomas et al., 2007). In the Challenger scheme, a series of reactions starting with arsenite produces
methylarsonic acid (MMAV ) which is reduced to methylarsonous
acid (MMAIII ) that is converted to dimethylarsinic acid (DMAV ) and
reduced to form dimethylarsinous acid (DMAIII ). In some species,
particularly rats and to lesser extent other rodents, DMAIII is further
methylated to form trimethylarsine oxide (TMAV O) (Adair et al.,
2007). TMAV O is only formed in humans when there is very high
exposure to inorganic arsenic (Aposhian, 1997; Cohen et al., 2006;
Thomas, 2007). These methylated metabolites of iAs exert speciﬁc
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toxicities in animal models. For example, DMAV produces urinary
bladder tumors in rats but is not carcinogenic in mice (Arnold et al.,
2006; Wei et al., 1999, 2002). DMAIII is thought to be the reactive metabolite that produces changes in the urothelium associated
with exposure to DMAV . Development of urinary bladder tumors
in DMAV -exposed rats is possibly related to regenerative proliferation caused by the cytotoxic effect of the reactive metabolite DMAIII
(Cohen et al., 2006, 2007; Waalkes et al., 2006). In contrast, MMAV
is negative as a carcinogen in rat and mouse bioassays (Arnold
et al., 2006) but is a transplacental carcinogen in the mouse (Tokar
et al., 2012). Thus, because the metabolism of iAs forms methylated
metabolites that are more reactive and toxic than the parent compound (Cohen et al., 2002; Petrick et al., 2000; Styblo et al., 2000), it
is likely that the methylated arsenicals contribute to the spectrum
of adverse health effects associated with chronic exposure to iAs
(Cohen et al., 2006).
Given the central role of arsenic methylation in the formation of
metabolites that mediate the toxic and carcinogenic effects associated with chronic exposure to iAs, manipulation of the capacity
to methylate arsenic is one approach to understanding underlying
molecular processes. Studies in As3mt knockout mice have shown
that this enzyme plays a central role in the control of the disposition and retention of arsenic in arsenate-treated mice (Drobna
et al., 2009; Hughes et al., 2010). Studies of the effects of arsenite
exposure in wild-type and As3mt knockout mice have shown that
changes in the urothelium are qualitatively similar but more pronounced in knockout mice than in wild-type mice (Chen et al., 2011;
Yokohira et al., 2010, 2011). The genotypic differences in the effects
of arsenite exposure on the urothelium can largely be explained by
the high retention of iAs in the urinary bladders of As3mt knockout
mice.
The present study examines effects on urothelial structure
after repeated exposure of wild-type and As3mt knockout mice to
DMAIII , the putative active metabolite of DMAV . Here, the As3mt
genotype affected morphological changes in the urothelium with a
greater response in As3mt knockout mice than in wild-type mice.
Evidence of regenerative proliferation in mice of either As3mt
genotype suggests that cytotoxicity and cell regeneration could
plausibly underlie urinary bladder tumorigenesis in the mouse.

2. Materials and methods
2.1. Chemicals
Dimethylarsinous iodide (DMAIII ) was obtained from Eurolabs Ltd. (Cheshire,
UK) and stored desiccated at 2–8 ◦ C. The purity of the chemical was greater than
95%. Bromodeoxyuridine (BrdU) was purchased from (Sigma–Aldrich, St. Louis, MO).
Nembutal (Lundbeck, Deerﬁeld, IL) was obtained from the Nebraska Medical Center
pharmacy.
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2.3. Animal experiment
All animals were placed in an Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC)-accredited facility and quarantined
for 7 days prior to treatment. The level of care provided met or exceeded the basic
requirements outlined in the Guide for the Care and Use of Laboratory Animals
(National Research Council, 2011). The animals were housed in polycarbonate cages
(5 per cage) with micro-isolator tops and dry corncob bedding. Nestlets (Ancare,
Bellmore, NY) were placed inside the cages for environmental enrichment. Animals
were maintained at approximately 22 ◦ C and 50% relative humidity with a 12-h
light/dark schedule, and were provided with pelleted Purina 5002 diet (Dyets Inc.,
Bethlehem, PA) and water (hyperchlorinated, RO) ad libitum throughout the study.
Animals were randomized into two groups per genotype. One group in each
genotype served as the control and the other group was administered 77.3 ppm
dimethylarsinous iodide (equivalent to 25 ppm elemental arsenic that previously
produced urothelial hyperplastic changes in these mice after 4 weeks of treatment (Yokohira et al., 2010, 2011)) in drinking water by injecting into water bags
(Hydropac® bags, Lab Products, Seaford, DE). Freshly prepared DMAIII was injected
into bags just before replacement. The water bags in both the control and DMAIII treated groups were replaced once every two days.
The animals were treated for four weeks. One hour before sacriﬁce the mice were
injected with BrdU, 100 mg/kg intraperitonially. At sacriﬁce the urinary bladders
were inﬂated in situ with Bouin’s ﬁxative, removed and placed in Bouin’s ﬁxative along with a small section of intestine. After ﬁxation, bladders were weighed,
observed macroscopically and divided in half longitudinally. One half of the bladder
was cut into longitudinal strips, embedded into parafﬁn with a slice of intestine,
sectioned and stained with hematoxylin and eosin for histopathological examination. A diagnosis of mild hyperplasia was made when there were four to ﬁve
cell layers in the bladder epithelium and moderate hyperplasia when six to eight
layers were present. Histopathological diagnosis is made without knowledge of
treatment group. The other half of each bladder was processed for examination
by scanning electron microscopy (EM) and classiﬁed in one of ﬁve categories as
previously described (Cohen et al., 1990). The categories have the following characteristics: class 1 bladders contain polygonal superﬁcial urothelial cells; class 2
bladders have occasional small foci of superﬁcial urothelial necrosis, especially in
the dome of the bladder; class 3 bladders have numerous small foci of superﬁcial
urothelial necrosis; class 4 bladders have extensive superﬁcial urothelial necrosis, especially in the dome of the bladder; class 5 bladders have necrosis and
piling up (hyperplasia) of rounded urothelial cells. Normal animals show class 1
or 2, or occasionally class 3. Kidneys were removed, ﬁxed in formalin, embedded in parafﬁn, sectioned and stained with hematoxylin and eosin and examined
histopathologically.
Unstained bladder and intestinal tissue slides were processed for immunohistochemical detection of BrdU (Cohen et al., 2007). Intestinal tissue served as a positive
control. Anti-BrdU (Millipore Corporation, Temecula, CA) was used at a dilution of
1:200. The BrdU-labeled cells in at least 3000 urothelial cells were counted to determine a labeling index. Microscopic examination and counting of BrdU-labeled cells
was done on blinded slides.
2.4. Statistics
Comparison of all data collected on body weights, food and water consumption,
bladder weights, and the labeling index was performed by the SAS general linear
models procedure and Duncan’s multiple range test. Selected intra-genotype and
inter-genotype comparisons for control and treated groups were performed. All
means are accompanied by calculation of standard errors. Histology results were
analyzed using Fisher’s Exact test (2-tail).

3. Results

2.2. Animals

3.1. General ﬁndings

2.2.1. As3mt knockout mice
Four female and two male mice homozygous for the disrupted As3mt gene
(Drobna et al., 2009) were obtained from Dr. David Thomas (U.S. Environmental
Protection Agency, Research Triangle Park, NC). Exons 3 through 5 were deleted
by homologous recombination to generate the As3mt KO homozygous mice. The
altered gene was introduced and maintained in strain 129S6 mice before being
introduced into strain C57BL/6 mice by marker-assisted accelerated backcrossing
performed by Charles River Laboratories (Wilmington, MA) to produce homozygous As3mt−/− mice. The mice were fertile, so brother/sister matings were used to
maintain the homozygous As3mt KO genotype. Twenty As3mt KO mice from the F6
generation, approximately 11 weeks old, were transferred from the breeding colony
at the University of Nebraska Medical Center, Omaha, NE.

All animals including treated KO mice showed no adverse signs,
and none died during the experimental period. There was no significant difference in body weight or food and water intake between
respective groups. There was a statistically signiﬁcant but small
increase of the relative kidney weight in treated compared to the
control knockout mice.

2.2.2. Wild type mice
Twenty female C57BL/6 mice (Charles River Breeding Laboratories, Kingston,
NY) approximately 11 weeks old at the time of arrival were used in the study.

3.2. Histopathology
Simple hyperplasia was observed in 4 of the 10 DMAIII -treated
knockout mice and only 2 of the 10 treated wild-type mice,
with none in the control knockout or wild-type mice (Fig. 1C,
F and Table 1). The superﬁcial layer of the urothelium contained eosinophilic intracytoplasmic granules (Suzuki et al., 2008)
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Figure 1. DMAIII -induced histopathological changes in the urothelium. Histopathological examination of the urothelium by hematoxylin and eosin staining showed normal
urothelium in knockout control mice (A) and the presence of eosinophilic intracytoplasmic granules in the superﬁcial layer of the urothelium (B) and simple hyperplasia (C)
in DMAIII -treated knockout mice. Similarly, wild-type control mice showed normal urothelium (D) and DMAIII -treated wild-type mice showed the presence of eosinophilic
intracytoplasmic granules (E) and simple hyperplasia (F). The granules in both knockout and wild-type mice appeared to be of various sizes and numbers per cell (B, E,
arrows). Magniﬁcation 1000× (A, B, D and E) and 200× (C and F).

in all DMAIII -treated mice (Fig. 1). Granules were round and of
varying sizes, with multiple granules occurring frequently in individual cells (Fig. 1B, E). The granules were slightly smaller and fewer
in treated wild-type mice compared to treated knockout mice.
None of the control mice had granules (Fig. 1A, D). The granules

were present in the DMAIII -treated bladders whether they had simple hyperplasia or were normal. The kidneys showed no remarkable
changes by histopathological examination, except one mouse
in the knockout-treated group showed focal, chronic interstitial
inﬂammation.

Table 1
Effects of DMAIII treatment on the urinary bladder epithelium in mice. Mice were administered 77.3 ppm (equivalent of 25 ppm arsenic) through drinking water for 4 weeks.
The urothelium was investigated for hyperplasia by hematoxylin and eosin staining, BrdU labeling index by immunohistochemistry, and visualization by scanning electron
microscopy (EM).
Group

Treatment

Strain

Histopathology

Normal
1
2
3
4
a
b

Control
77.3 ppm DMAIII
Control
77.3 ppm DMAIII

KO
KO
WT
WT

10
6
10
8

Signiﬁcantly different compared to KO control group, p < 0.05.
Signiﬁcantly different compared to the WT DMAIII group, p < 0.05.

BrdU labeling
index (%)
Mean ± S.E. (n)
Simple hyperplasia
0
4
0
2

0.11
0.75
0.20
0.08

±
±
±
±

0.06 (9)
0.27 (9)a , b
0.14 (9)
0.03 (10)

SEM classiﬁcation

1

2

3

4

3
2
3
5

5
4
5
4

1
4
2
1

1
0
0
0
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Figure 2. Scanning electron microscopy (EM) examination of the bladder urothelium. Urothelium of control knockout mice was normal in appearance (A, bar = 300 m)
whereas necrosis and exfoliation of the superﬁcial cells was present in the bladder urothelium from DMAIII -treated As3mt knockout mice (B, bar = 500 m). In the wild-type
mice, the urothelium was normal in both control (C, bar = 200 m) and DMAIII -treated (D, bar = 300 m) groups.

3.3. Scanning electron microscopy

4. Discussion

Although the changes visualized by EM were not statistically
signiﬁcant, there was a clear trend for DMAIII -induced cytotoxicity
in the treated knockout mice compared to other groups (Table 1
and Fig. 2). The DMAIII -treated knockout mice had only 2 bladders
with class 1 changes and 4 bladders with class 2 changes, which are
considered normal for rodents (Cohen et al., 1990). However, four
bladders in the same group showed class 3 changes, which contain numerous small foci of superﬁcial urothelial necrosis (Fig. 2B),
whereas the knockout control group had 3 and 5 bladders with class
1 and class 2 changes (Fig. 2A), respectively, and only one each with
class 3 and class 4 changes. Among the wild type, DMAIII -treated
mice there was no signiﬁcant cytotoxicity in the bladder by EM
compared to the control group (Fig. 2C, D).

Results of the present study showed that DMAIII administration
in drinking water for four weeks induced urothelial cytotoxicity
and regenerative urothelial cell proliferation in As3mt knockout
mice which was somewhat greater compared to the treated wildtype mice. DMAIII induced formation of intracytoplasmic granules
in the superﬁcial urothelial cell layer in both wild-type and knockout mice. There were no instances of systemic toxicity in wild-type
or knockout mice.
DMAIII induced simple hyperplasia in more knockout mice
compared to wild-type mice, however the increase was not statistically signiﬁcant. This was further demonstrated by a signiﬁcant
increase in BrdU labeling index in treated knockout mice, indicating increased cell proliferation leading to simple hyperplasia; the
labeling index was not increased in wild type mice. These results
are similar to what we have observed for arsenite-administered
As3mt knockout compared to wild-type mice (Yokohira et al.,
2010, 2011). However, in the As3mt knockout mice, arsenite
induced more pronounced systemic toxicity at comparable doses
than in wild-type mice (Yokohira et al., 2010, 2011). This was
attributed to decreased clearance of arsenite in the As3mt knockout

3.4. BrdU labeling index
The DMAIII -treated knockout mice had a signiﬁcantly increased
BrdU labeling index compared to the knockout control group and
also compared to the DMAIII -treated wild-type group of mice.
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mice (Drobna et al., 2009; Yokohira et al., 2010, 2011). Methylation enhances the clearance of arsenic through urine (Cohen
et al., 2006; Kenyon et al., 2008), but in As3mt knockout mice,
arsenic is cleared slowly and accumulates in the tissues (Chen
et al., 2011). In the current study, there was a signiﬁcant difference between the DMAIII -induced effects in As3mt knockout
mice compared to wild-type mice, suggesting either that DMAIII
is not cleared as efﬁciently as in the wild-type mice, or loss
of As3mt function makes the urothelium more susceptible to
DMAIII . The ﬁrst explanation is more likely. Mice are known to
methylate DMA to TMAV O but only to a limited extent (Cohen
et al., 2006). DMA (DMAIII + DMAV ) remains the major metabolite excreted in urine (Cohen et al., 2006). This suggests that
wild-type mice may further methylate a signiﬁcant quantity of
DMAIII to TMAV O, which is less reactive and less cytotoxic and
will reduce the net DMAIII excreted in the urine. Metabolic
and kinetic analyses are required to distinguish these possibilities.
DMA (DMAIII + DMAV ) is the major metabolite in people exposed
to inorganic arsenic and also in rats and mice exposed to arsenate, arsenite, MMAV and DMAV (Cohen et al., 2006). Among the
arsenicals studied in 2-year bioassays DMAV was carcinogenic to
the bladder in rats but not mice (Arnold et al., 2006). Arsenate
and arsenite are carcinogenic to mice, although the carcinogenic
effect on the urothelium is limited (Cohen et al., 2007; Tokar
et al., 2010; Waalkes et al., 2006). Interestingly, MMAV was not
carcinogenic to either mice or rats (Arnold et al., 2003). In short
term studies in rats, orally administered arsenate, arsenite and
DMAV induced urothelial hyperplasia, the preneoplastic proliferative lesion of the urothelium (Cohen et al., 2007). Arsenate and
arsenite also induced urothelial hyperplasia in mice, but DMAV did
not (Arnold et al., 2006; Cohen et al., 2006). The data in the current study show that DMAIII also induces simple hyperplasia of
the urothelium in mice, suggesting a role for DMAIII in the inorganic arsenic-induced pre-neoplastic changes and carcinogenic
effects.
We have previously reported the detection of numerous intracytoplasmic and intranuclear granules in AsIII -treated mice (Suzuki
et al., 2008; Yokohira et al., 2010, 2011). In this study, DMAIII
also induced intracytoplasmic granules in both As3mt knockout
and wild-type mice. These granules were conﬁned to the superﬁcial layer and were seen in bladders with or without simple
hyperplasia. Our earlier study showed the presence of granules
in all layers of the urothelium in inorganic arsenic-administered
to As3mt knockout mice, and the severity of granule formation
was dose-dependent (Yokohira et al., 2010, 2011). Compared to the
arsenic-equivalent concentration of inorganic arsenic used in the
previous studies, the severity of granule formation by DMAIII was
less in terms of both number of granules and the layers of urothelium affected. This may be due to faster clearance of pre-methylated
DMAIII compared to non-methylated inorganic arsenic. The significance or the role of these granules in arsenic-induced toxicity is
still unclear.
The current study demonstrated that DMAIII induces urothelial cytotoxicity and regenerative proliferation in As3mt knockout
mice and to a lesser extent in the wild-type mice, unlike DMAV
that did not induce any urothelial changes in wild type mice
(Arnold et al., 2006; Cohen et al., 2006). Similar to inorganic
arsenic, DMAIII induced formation of intracellular granules in
the urothelium of both As3mt knockout and wild-type mice,
though to a lesser extent than inorganic arsenic. These results
support our hypothesis that urothelial toxicity is induced by
reactive arsenicals, including DMAIII , which is a highly reactive,
trivalent methylated arsenical. Cytotoxicity is followed by regenerative proliferation resulting in hyperplasia and ultimately possibly
tumors.
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